×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
YMAB – y-mabs therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
YMAB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/23
07:30 am
ymab
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/20
09:04 am
ymab
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely [Yahoo! Finance]
Low
Report
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely [Yahoo! Finance]
12/11
08:21 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright.
12/7
12:06 pm
ymab
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting [Yahoo! Finance]
Low
Report
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting [Yahoo! Finance]
12/7
12:00 pm
ymab
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Low
Report
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
12/6
05:31 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Low
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
12/5
08:01 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $17.00 price target on the stock.
Medium
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $17.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/8/2024
06:35 am
YMAB
y-mabs therapeutics, inc.
MISS
Report
-4.7%
y-mabs therapeutics, inc.
8/12/2024
06:30 am
YMAB
y-mabs therapeutics, inc.
MISS
Report
-23.5%
y-mabs therapeutics, inc.
5/7/2024
04:05 pm
YMAB
y-mabs therapeutics, inc.
MISS
Report
-20.9%
y-mabs therapeutics, inc.
2/29/2024
04:05 pm
YMAB
y-mabs therapeutics, inc.
BEAT
Report
11.9%
y-mabs therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:33 pm
ymab
Form SC 13G/A Y-mAbs Therapeutics, Filed by: Paradigm Biocapital Advisors LP
Low
Report
Form SC 13G/A Y-mAbs Therapeutics, Filed by: Paradigm Biocapital Advisors LP
11/12
06:01 pm
ymab
Form SC 13G/A Y-mAbs Therapeutics, Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Y-mAbs Therapeutics, Filed by: VANGUARD GROUP INC
11/8
07:19 am
ymab
Form 10-Q Y-mAbs Therapeutics, For: Sep 30
Low
Report
Form 10-Q Y-mAbs Therapeutics, For: Sep 30
11/8
06:56 am
ymab
Form 8-K Y-mAbs Therapeutics, For: Nov 08
Low
Report
Form 8-K Y-mAbs Therapeutics, For: Nov 08
11/4
02:16 pm
ymab
Form SC 13G/A Y-mAbs Therapeutics, Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Y-mAbs Therapeutics, Filed by: VANGUARD GROUP INC
11/4
08:51 am
ymab
Form 8-K Y-mAbs Therapeutics, For: Oct 29
Low
Report
Form 8-K Y-mAbs Therapeutics, For: Oct 29
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Form 4 Y-mAbs Therapeutics, For: Mar 17 Filed by: Moller-San Pedro Claus Juan
22.2%
3/18 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 10.2%
3/13 YmAbs Therapeutics, Inc. (YMAB) Q4 2019 Earnings Call Transcript [The Motley Fool] 9.7%
3/24 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 9.3%
1/15 Form 4 Y-mAbs Therapeutics, For: Jan 13 Filed by: Gad Thomas 9.1%
10/31 Form 8-K Y-mAbs Therapeutics, For: Oct 29 7.9%
4/21 Form 8-K Y-mAbs Therapeutics, For: Apr 15 5.8%
5/14 Form 4 Y-mAbs Therapeutics, For: May 13 Filed by: Gad Thomas 5.7%
6/8 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 5.2%
1/22 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 5.2%
3/18 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 10.2%
3/13 YmAbs Therapeutics, Inc. (YMAB) Q4 2019 Earnings Call Transcript [The Motley Fool] 9.7%
3/24 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 9.3%
1/15 Form 4 Y-mAbs Therapeutics, For: Jan 13 Filed by: Gad Thomas 9.1%
10/31 Form 8-K Y-mAbs Therapeutics, For: Oct 29 7.9%
4/21 Form 8-K Y-mAbs Therapeutics, For: Apr 15 5.8%
5/14 Form 4 Y-mAbs Therapeutics, For: May 13 Filed by: Gad Thomas 5.7%
6/8 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 5.2%
1/22 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 5.2%
TOP News Decliners
7/1
Form 8-K Y-mAbs Therapeutics, For: Jul 01
-21.3%
3/14 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -16.7%
10/29 Y-mAbs Announces Proposed Public Offering of Common Stock -10.1%
5/10 Q1/2019 3/31/2019 EPS -0.470 ZacksConsensus N/A ActVsEst N/A - N/A -10.0%
3/5 Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020 -8.7%
6/15 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. -6.9%
8/3 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $26.00 price target on the stock. -6.1%
2/27 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.7%
11/1 Form 8-K Y-mAbs Therapeutics, For: Oct 31 -5.6%
10/12 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. -5.1%
3/14 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -16.7%
10/29 Y-mAbs Announces Proposed Public Offering of Common Stock -10.1%
5/10 Q1/2019 3/31/2019 EPS -0.470 ZacksConsensus N/A ActVsEst N/A - N/A -10.0%
3/5 Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020 -8.7%
6/15 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. -6.9%
8/3 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $26.00 price target on the stock. -6.1%
2/27 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.7%
11/1 Form 8-K Y-mAbs Therapeutics, For: Oct 31 -5.6%
10/12 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. -5.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: